DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Opinion
Video

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

Related Videos
Stephen V. Liu, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 5 experts on lung cancer
Related Content
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article
Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024
Podcast
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024
Article
Diane M. Simeone, MD; Marwan G. Fakih, MD

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023
Podcast
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Anne Chiang, MD, PhD, of Yale School of Medicine

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024
Article